Date
Attendees
Committee Member | Present | Absent |
---|---|---|
X | ||
X | ||
X | ||
X | ||
X | ||
Debbie Knapp | X | |
Toby Hecht | X | |
X |
Goals
- Discuss updates to ICDC and define emerging strategies and priorities
SharePoint Site
https://nih.sharepoint.com/sites/NCI-CBIIT-FNL-ICDC-ICDCLeadershipGroups
Outstanding Action Items
Agenda
Item | Who | Talking Points |
---|---|---|
DGAB Updates | ICDC Studies in the Queue
| |
BPSC Updates |
| |
Upcoming Steering Committee Meeting |
|
Minutes (Not Verbatim)
TH - Look at drug responses and the tumor itself to determine if there is a biomarker based on genomic expression. In the Intro of the BPSC paper, we could give examples of things that can be done based upon existing drug trial studies.
AL - In general, there is such a scarcity of credentialed biology in tumor progression. Drug mechanisms can be highlighted with an imaging reporter.
DK - Pre and post biopsies were attempted in Vemurafinib trial
AL - Until we have DBs to refer to and a more stable reference genome it is difficult to make progress.
Previous ICDC Use Cases from Steering Committee
1. Genomic correlates across platforms (DNA, RNA, protein).
2. Correlating multi-omics data with clinical annotation and phenotypes, particularly outcomes.
3. Comparative analyses of canine and human. Examples include:
1. Search for conserved mutations between canine and human tumors
2. Disease diagnosis (e.g. cancer type) and classification mapping between canines and humans
5. Gene expression changes and mutational profiles associated with therapeutic response and outcome
6. How do sporadic tumors in non-human mammals compare to sporadic human tumors?
7. Correlations and model building from radiomic and pathomic features extracted from medical and histopathologic images with outcomes and genomics, as is currently being widely done with human images
8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.
Previous Meeting Minutes (Not Verbatim)
TH - Circulating tumor DNA is a strong candidate for the next phase of the ICDC.
CS - There is a grant under the mammalian models from Cheryl London and co.
Action items